RADLY.US Raia Drogasil SA ADR
- Market cap
- USD 4.32B
- P/E
- 16.5x
- P/B
- 3.23x
- ROE
- 17.7%
- Dividend yield
- 3.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RADLY.US undervalued?
Graham numberRADLY.US trades 53.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Raia Drogasil SA ADR fundamental analysis
No fundamental analysis for Raia Drogasil SA ADR yet.
Raia Drogasil SA ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Raia Drogasil SA ADR
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.
Full company profileRaia Drogasil SA ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Raia Drogasil SA ADR annual financial statements (BRL; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.3B | 13.2B | 14.8B | 17.6B | 20.1B | 24.1B | 29.1B | 34.0B | 38.9B | 43.4B | 44.4B |
| Gross Profit | 3.50B | 3.99B | 4.45B | 5.20B | 5.89B | 7.21B | 8.81B | 10.2B | 11.5B | 10.7B | 13.9B |
| Operating Income | 706M | 793M | 722M | 785M | 854M | 1.22B | 1.48B | 2.08B | 2.37B | 2.59B | 3.14B |
| EBITDA | 966M | 1.11B | 1.09B | 2.10B | 2.08B | 2.63B | 3.26B | 2.75B | 3.14B | 4.54B | 5.05B |
| Net Income | 448M | 511M | 502M | 772M | 484M | 752M | 996M | 1.05B | 1.20B | 1.27B | 1.34B |
| EPS | 0.26 | 0.30 | 0.29 | 0.45 | 0.28 | 0.44 | 0.58 | 0.62 | 0.72 | 0.77 | 0.80 |
| Balance Sheet | |||||||||||
| Total Assets | 5.66B | 6.46B | 7.35B | 12.2B | 13.8B | 14.8B | 17.2B | 20.1B | 22.1B | 25.5B | 25.6B |
| Total Liabilities | 2.72B | 3.21B | 3.82B | 8.17B | 9.40B | 10.1B | 11.8B | 14.1B | 15.7B | 18.1B | 18.1B |
| Shareholders' Equity | 2.91B | 3.22B | 3.50B | 4.03B | 4.36B | 4.68B | 5.34B | 5.96B | 6.43B | 7.32B | 7.55B |
| Cash & Short-term Investments | 277M | 265M | 242M | 299M | 880M | 356M | 434M | 412M | 544M | 528M | 627M |
| Total Debt | 414M | 611M | 843M | 4.31B | 5.08B | 5.18B | 6.06B | 7.07B | 7.70B | 8.83B | 8.83B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 556M | 629M | 683M | 965M | 1.48B | 1.55B | 1.68B | 963M | 1.91B | 2.38B | 2.74B |
| Capital Expenditure | 490M | 640M | 703M | 287M | 676M | 856M | 1.19B | 1.30B | 1.28B | 1.38B | 1.41B |
| Free Cash Flow | 65.4M | -11.5M | -20.1M | 679M | 801M | 695M | 493M | -342M | 629M | 1.01B | 1.33B |
| Ratios | |||||||||||
| ROE | 15.4% | 15.9% | 14.4% | 19.2% | 11.1% | 16.1% | 18.7% | 17.7% | 18.6% | 17.4% | 17.7% |
| ROA | 7.9% | 7.9% | 6.8% | 6.3% | 3.5% | 5.1% | 5.8% | 5.3% | 5.4% | 5.0% | 5.2% |
| Net Profit Margin | 4.0% | 3.9% | 3.4% | 4.4% | 2.4% | 3.1% | 3.4% | 3.1% | 3.1% | 2.9% | 3.0% |
| Debt to Equity | 0.14x | 0.19x | 0.24x | 1.07x | 1.17x | 1.11x | 1.13x | 1.19x | 1.20x | 1.21x | 1.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Raia Drogasil SA ADR dividends
- Dividend yield
- 3.53%
- Forward dividend
- 0.09 USD
- Payout ratio
- 50.3%
- Ex-dividend date
- Oct 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | BRL 640M | 0.39 | 50.3% |
| 2024 | BRL 475M | 0.29 | 39.6% |
| 2023 | BRL 466M | 0.27 | 44.2% |
| 2022 | BRL 324M | 0.19 | 32.5% |
| 2021 | USD 265M | 0.15 | 35.2% |
| 2020 | USD 191M | 0.11 | 39.3% |
| 2019 | USD 187M | 0.11 | 24.2% |
| 2018 | USD 174M | 0.10 | 34.6% |
| 2017 | BRL 171M | 0.10 | 33.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Oct 1, 2020.
Who owns Raia Drogasil SA ADR
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 1.75B
- Free float 1.30B
Raia Drogasil SA ADR company profile
- Company name
- Raia Drogasil SA ADR
- Ticker
- RADLY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Consumer Staples Distribution & Retail
- Employees
- 77,428
- Fiscal year end
- December
- Address
- Av. Corifeu de Azevedo Marques, 3097, São Paulo, SP, Brazil, 05339-900
- Phone
- 55 11 3769 5678
- Website
- rdsaude.com.br
About Raia Drogasil SA ADR
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.
Raia Drogasil SA ADR management
10- Mr. Renato Cepollina RaduanCEO & Member of Executive Board
- Mr. Antonio Carlos CoelhoVP of Finance & Administrative and Member of Executive Board
- Mr. Marcello De ZagottisCOO & Member of Executive Board
- Mr. Fernando Kozel VarelaVP of Digital Transformation & Member of Executive Board
- Mr. Bruno Wright PipponziVP of Health Business & Member of Executive Board
- Celso Pissi FilhoAccountant & Technical Manager
- Erika PetriVice President of People & Sustainability
- Juliana Lopes Marques PaixaoCommercial Vice President
- Ms. Melissa Teixeira CabralVice President of Pharmacy Operations
- Afonso Celso Florentino de OliveiraDirector of Controllership